Wednesday, 05 September 2007
Eli Lilly (LLY) Select Joint Ventures, Partnerships, and Alliances with Big Pharma
Eli Lilly and Daiichi Sankyo – are engaged in a Phase III head-to-head study comparing prasugrel to clopidogrel (Plavix®) in patients with acute coronary syndrome – January 2007. (source: PR Newswire, Eli Lilly press release http://www.prnewswire.com/cgi-bin/micro_stories.pl?ACCT=916306&TICK=LLY&STORY=/www/story/10-23-2006/0004457213&EDATE=Oct+23,+2006)
Eli Lilly and Millennium entered into a strategic alliance in oncology in 1996. Lilly renewed the agreement in 1999 based on Millennium's successful pipeline of novel genes and targets for drug discovery. The two companies also have a strategic alliance in congestive heart failure. (Source: Millennium's 10-K annual report) sec.edgar-online.com/1997/03/31/00/0000950135-97-001513/Section2.asp
Eli Lilly and Merck – In November 2004 Lilly acquired the rights to develop a Merck compound called EMD 281014, currently in Phase I clinical trials for the treatment of insomnia. Merck KGaA retains rights for potential co-promotion of the product in certain countries. TheStreet.com reports that "Under the terms of the agreement, the German company will receive an upfront payment of $29 million during the fourth quarter as well as milestone and royalty payments based on the drug's development and commercialization." http://www.thestreet.com/stocks/biotech/10190804.html
Eli Lilly and Boehringer Manheim – entered into a Diabetes-treatment alliance in 1994. (source: healthwire) http://findarticles.com/p/articles/mi_m0EIN/is_1994_Nov_7/ai_15896373
Eli Lilly and Amylin Pharmaceuticals – received European Commission authorization to market Byetta® as a treatment for type 2 diabetes – November 2006. (Source: Eli Lilly SEC 10-K filing for FY2006). Available at: http://biz.yahoo.com/e/070228/lly10-k.html
Select Joint Ventures, Partnerships, and Alliances with Small Pharma and Other Organizations
Eli Lilly and Lonza biologics plc.- Xigris. – Lilly and Lonza entered into a co-promotion agreement for Xigris, a treatment for sepsis, in 1997. According to the alliances website for Lonza, "The estimated cost associated with the treatment of patients with sepsis range from $10 Billion to $25 Billion annually in the U.S. alone."
Eli Lilly and Amylin Pharmaceuticals – jointly developed and launched BYETTA®, a therapy for blood-sugar control. According to Healthcentral.com, "The drug's sales were $146.5 million in the first quarter [of 2007]." http://www.healthcentral.com/diabetes/news-37701-66.html
Eli Lilly and GlycoFi – In October 2005 entered into a research and commercialization alliance for a variety of therapeutic proteins and antibodies. According to a GlycoFi press release, "Under the terms of the agreement Lilly will make an equity investment in GlycoFi, pay an upfront cash payment, and fund all of the expenses associated with the research. If Lilly decides to develop and commercialize the collaboration drug candidates, GlycoFi will receive milestone payments for each compound and royalties on the sales of the products that result from the collaboration." http://www.glycofi.com/100305.htm
Eli Lilly and Isis Pharmaceuticals, Inc were awarded the Breakthrough Alliance Award of 2002 for a strategic alliance which included Isis' licensing its Phase III antisense cancer drug (Affinitac) and for a broader alliance for the discovery of new antisense cancer drugs – August 2001. http://goliath.ecnext.com/coms2/gi_0199-1727917/Isis-Pharmaceuticals-and-Lilly-s.html
Eli Lilly and Alkermes – are engaged in two separate collaborations to utilize Alkermes' proprietary AIR™ pulmonary drug delivery system to develop inhaled formulations of human growth hormone, and short- and long-acting formulations of insulin as well as other products used to treat diabetes – (source: Alkermes, Inc. press release) http://www.lilly.com/about/partnering/alliances/research/alkermes.html
Eli Lilly and Nicholas Piramal India Limited – In January 2007 signed an agreement to develop and commercialize select pre-clinical drug candidates in several areas. According to FierceBiotech.com, "NPIL will be responsible for the design and execution of the global clinical development program, including IND-enabling non-clinical studies and human clinical trials up to Phase III. NPIL would receive a call-back payment, and potential milestone payments of up to $100 million, plus royalties on sales upon successful launch of the first compound. The agreement, which will serve as a prototype for joint development of several pre-clinical drug candidates from Lilly in multiple therapeutic areas, will be a new paradigm for global alliances in drug discovery and development." http://www.fiercebiotech.com/node/5212?utm_source=related&utm_medium=internal
Other Affiliations
Eli Lilly and the National Alliance for the Mentally Ill (NAMI) – Gardiner Harris of the New York Times reports that the National Alliance for the Mentally Ill (NAMI), which presents itself as a consumer advocacy group, is actually funded by major pharmaceutical companies, most notably Eli Lilly. Mr. Harris details lobbying efforts by Lilly's front company in the state legislatures of New York, Kentucky, Oregon, and on Capitol Hill to keep an expensive antipsychotic, Zyprexa, on Medicaid preferred drug lists. (Source: Harris, Gardiner. "States Try to Limit Drugs in Medicaid, but Makers Resist." The New York Times, 18 December 2003.
Eli Lilly and the Homeland Security Act – Bruce Levine of zmag.org reports that, "In 2002, Eli Lilly flexed its muscles at the highest level of the U.S. government in…the signing of the Homeland Security Act." The provision tacked onto the bill exempted Eli Lilly and other big pharma companies from lawsuits related to Thimerosal, a preservative containing mercury used in Lilly's vaccines. The Levine article also notes that, "The punchline…is that, in June 2002, President George W. Bush had appointed Eli Lilly’s CEO, Sidney Taurel, to a seat on his Homeland Security Advisory Council. Ultimately, even some Republican senators became embarrassed by this…and, by early 2003, moderate Republicans and Democrats agreed to repeal this particular provision in the Homeland Security Act." http://zmagsite.zmag.org/May2004/levine0504.html